Singular Genomics Systems, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
8-K: Singular Genomics Acquired by Deerfield Management for $20 Per Share, Transitions to Private Company
Singular Genomics Systems, Inc. has completed its acquisition by Deerfield Management Company, transitioning to a private company after satisfying customary closing conditions.
Singular Genomics Systems' stockholders approved the merger agreement with Singular Genomics Parent, LLC Inc. at a special meeting held on February 19, 2025.
8-K: Singular Genomics Faces Lawsuits Over Merger Disclosures, Voluntarily Supplements Proxy Statement
Singular Genomics Systems, Inc. is supplementing its proxy statement related to its merger with a Deerfield Management affiliate following lawsuits alleging misleading disclosures.
Singular Genomics Systems, Inc. has agreed to be acquired by an affiliate of Deerfield Management Company, L.P. for $20.00 per share in cash.
Singular Genomics announced its third quarter 2024 financial results, highlighted by the shipment of the first G4X Early Access instrument and progress in spatial sequencing technology.
Singular Genomics has entered an exclusivity agreement with Deerfield Management for a potential acquisition at $24 per share, following a competitive process.
Singular Genomics has received a non-binding acquisition proposal from Concentra Biosciences to acquire all outstanding shares for $12 per share in cash, with a potential alternative of a contingent value right.
Deerfield Management has proposed to acquire Singular Genomics for $10 per share in cash, prompting the formation of a special committee to evaluate the offer.
Singular Genomics announced its second quarter 2024 financial results, highlighted by $0.7 million in revenue and progress in the development of its G4X Spatial Sequencer.
Singular Genomics Systems, Inc. has amended its lease agreement to reduce its office and laboratory space in San Diego, resulting in a one-time payment of $4.5 million.
Singular Genomics has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
Singular Genomics Systems, Inc. has completed a 1-for-30 reverse stock split, effective June 26, 2024, to consolidate its outstanding shares.
Singular Genomics Systems held its 2024 Annual Meeting, where stockholders approved the election of directors, ratified the appointment of Ernst & Young LLP, and authorized a reverse stock split.
Singular Genomics reported $0.4 million in revenue for Q1 2024, shipped six G4 systems, and highlighted progress on the G4X spatial sequencer.
Singular Genomics announced a 41% increase in revenue for the fourth quarter of 2023, driven by increased instrument shipments, and unveiled their new G4X spatial sequencer.
Singular Genomics Systems, Inc. has received approval to transfer its stock listing to the Nasdaq Capital Market, granting them an extension to regain compliance with minimum bid price requirements.